Clinical Trials List
2024-05-01 - 2029-12-31
Phase III
Recruiting10
ICD-10E78.0
Pure hypercholesterolemia
ICD-9272.0
Pure hypercholesterolemia
A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/24
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 李應湘 Division of Cardiovascular Diseases
- 洪崇烈 Division of Cardiovascular Diseases
- 程崇偉 Division of Cardiovascular Diseases
- 簡禎彥 Division of Cardiovascular Surgery
- 李俊偉 Division of Cardiovascular Diseases
- 洪大川 Division of Cardiovascular Diseases
- 陳律安 Division of Neurology
- 劉俊傑 Division of Cardiovascular Diseases
- 林書毅 Division of Cardiovascular Diseases
- 郭任遠 Division of Cardiovascular Diseases
- 蘇正煌 Division of Cardiovascular Diseases
- 吳懿哲 Division of Cardiovascular Diseases
- 林肇鋒 Division of Cardiovascular Diseases
- 陳俊延 Division of Cardiovascular Diseases
- 廖峰慶 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳隆景 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chien-Yi Hsu Division of Cardiovascular Diseases
- 鄭宇倫 Division of Cardiovascular Diseases
- Yung-Ta Kao Division of Cardiovascular Diseases
- 蕭卜源 Division of Cardiovascular Diseases
- 陳志維 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 王植賢 Division of General Surgery
- JEN-KUANG LEE Division of General Internal Medicine
- MAO-HSIN LIN Division of General Internal Medicine
- 陳盈憲 Division of General Internal Medicine
- Chih-Fan Yeh Division of General Internal Medicine
- Yi-Chih Wang Division of General Internal Medicine
- Chau-Chung Wu Division of General Internal Medicine
- 林柏志 Division of General Internal Medicine
- WEI-TIEN CHANG Division of Emergency Medicine
- 黃慶昌 Division of General Internal Medicine
- 蘇大成 Division of General Internal Medicine
- 江君揚 Division of General Internal Medicine
- LIAN-YU LIN Division of General Internal Medicine
- 柯宗佑 Division of General Internal Medicine
- 賀立婷 Division of General Internal Medicine
- 蔡承烜 Division of General Internal Medicine
- Tzung-Dau Wang Division of General Internal Medicine
- CHO-KAI WU Division of General Internal Medicine
- YEN-HUNG LIN Division of General Internal Medicine
- Hsien Li Kao Division of General Internal Medicine
- CHIEN-HUA HUANG Division of Emergency Medicine
- 鄭人方 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chin-Sung Kuo Division of Endocrinology
- 蘇冠伃
- 張俊欽 Division of Cardiovascular Diseases
- 蘇冠伃 Division of Endocrinology
- 吳崇暉 Division of Endocrinology
- 黃金洲 Division of Cardiovascular Diseases
- Chii-Min Hwu Division of Endocrinology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ming-Shien Wen Division of Cardiovascular Diseases
- 陳俊吉 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張獻元 Division of Cardiovascular Diseases
- 黃鼎鈞 Division of Cardiovascular Diseases
- 柯呈諭 Division of Cardiovascular Diseases
- 黃睦翔 Division of Cardiovascular Diseases
- 李文煌 Division of Cardiovascular Diseases
- Po-Sheng Chen Division of Cardiovascular Diseases
- Po-Tseng Lee Division of Cardiovascular Diseases
- 陳柏偉 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Has completed an enlicitide decanoate (also known as enlictide and MK-0616) parent study [MK-0616-013 (NCT05952856), MK-0616-017 (NCT05952869), and MK-0616-018 (NCT06450366)] per protocol (including the final assessments/procedures of their parent study)
Had an overall study intervention compliance ≥80% while participating in their parent study
Exclusion Criteria
Has discontinued study intervention in their parent study
Has an ongoing serious adverse event considered related to study intervention by the investigator in the parent study
Is planning to begin treatment with a nonstudy protein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) while enrolled in the study
Is currently participating in an interventional clinical study other than an enlicitide decanoate parent study
The Estimated Number of Participants
-
Taiwan
250 participants
-
Global
3000 participants
